Nobody ever rings a bell. Nobody ever says sell, stay out, stand aside, stay 100% in cash, earn >5% interest. Let #GFEX crash -32% & drag stocks down -38%, -50%, -75% in a second rapid multi-week GFEX >30% bear market plunge in 2026 as perma-bulls chant the #BESS is yet to come.
Sacrificing your relationships with family and friends who care about you, in order to be more "successful" and get more validation from a society of strangers who actually don't care about you is never a good deal, but sadly, many people can't see it until it's already too late.
🫀💊 The aspirin conundrum—solved (partly) by genetics
This 2025 American Journal of Preventive Cardiology State-of-the-Art Review tackles one of the longest-running dilemmas in prevention: why does low-dose aspirin help some people—but harm others? The answer may lie in Lp(a) genetics .
⚖️ The classic problem
In primary prevention, aspirin reduces myocardial infarction—but increases major bleeding to a similar extent. At the population level, benefits and harms cancel out, leading guidelines to largely step back from routine aspirin use.
🧬 Enter Lp(a) and the LPA genotype
The review focuses on a specific LPA polymorphism (rs3798220), present in ~3–4% of individuals, strongly associated with:
markedly elevated Lp(a) levels
increased atherothrombotic risk
Crucially, three large studies (Women’s Health Study, ARIC, ASPREE) show a consistent pattern:
In LPA-negative individuals → aspirin provides minimal benefit (very high NNT: 250–800)
In LPA-positive individuals → aspirin dramatically reduces cardiovascular events, bringing their risk down to the level of non-carriers
📊 The numbers matter
In LPA carriers:
Relative risk reduction: ~55–80%
Absolute risk reduction: ~2.7–3%
Number needed to treat (NNT): ~34–38👉 Comparable to, or better than, many statin trials.
🧠 Why this makes sense biologically
Lp(a) promotes thrombosis via its plasminogen-like structure. Aspirin doesn’t lower Lp(a) levels—but may neutralize its pro-thrombotic effect.
⚠️ Important caveats
Evidence is based on post-hoc genetic analyses
Most data come from European ancestry
Bleeding risk still exists and must be individualized
🔮 Bottom line
This paper reframes aspirin not as a blunt population tool—but as a precision therapy.
👉 For most people, aspirin isn’t worth it.
For a genetically defined few, it may be exactly right.
🧭 Sometimes, the problem isn’t the drug—it’s who we give it to.
Sharjah, 2002. Batting on 70 in 40°C heat, Ricky Ponting ditched the helmet for a cap🤯
Then, a Mohammad Sami bouncer hit him flush on the jaw. Most would’ve walked. Punter? He just spat blood, adjusted his cap, and smashed 150🔥
Pure swagger. Pure grit. The ultimate fighter🤯
Wishing all a healthy and fulfilling 2026! The "Lp(a) Hypothesis" is close to being revealed- will moving Lp(a) levels from red to green with pelacarsen lead to clinical benefit (besides known effect on lowering Lp(a))?. This will be the most anticipated CVD outcomes trial of 2026. No matter the outcome, the results will be very helpful in managing our patients with elevated Lp(a).
Major cheat code for life: Don’t mourn the time you lost, use the time you still have. Most people walk around haunted by a list of things they wish they’d done by now. They tell themselves it’s too late. It’s not. Six months from now, it can still be a wish, or it can be real.
10 years of “perfect” bloodwork on a plant-based diet, but I still found plaque in my arteries. In this episode, I unpack my CT angiogram results with Drs. Thomas Dayspring and Dan Soffer.
https://t.co/cjaFYMbZch
And #WallStreet#ShortSellers knew it and loaded up their short positions on lithium producers and waited to profit as revenue & earnings downgrades were announced each quarter as LCE spot prices kept falling from the Nov 2022 euphoric peak in the subsidy-fuelled lithium boom.